Jing Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jing Zhou has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Rui Li
Department of Neurology, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
2 shared publications - Yuge Wang
Department of Neurology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
2 shared publications - Bingjun Zhang
Department of Neurology The Third Affiliated Hospital of Sun Yat‐Sen University Guangzhou China
1 shared publication Haotian Wu
Department of Neurology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
1 shared publication- Juanjuan Chen
Department of Neurology, Peking University Shenzhen Hospital, China
1 shared publication - Wei Qiu
Department of Neurology The Third Affiliated Hospital of Sun Yat‐Sen University Guangzhou China
1 shared publication
Latest Publications
- Open Access
- 16 May 2024
- Published by Springer Nature in Neurology and Therapy
- Vol. 13 (4) , 1117-1133
Sustained Effectiveness and Safety Over Time of Teriflunomide in Chinese Patients with Relapsing Multiple Sclerosis in the Greater Bay Area of China: Insights from Real-World Data
Introduction The real-world data on the medium- to long-term effectiveness and safety of teriflunomide in Chinese patients with relapsing multiple sclerosis (MS) is limited. Therefore, this study aims to assess the treatment outcomes of teriflunomide in Chinese patients with MS over a medium- to long-term period. Methods This cohort study was carried out in three tertiary hospitals and regional MS centers located in the Greater Bay Area of China. We obtained the historical clinical data of patients who underwent teriflunomide treatment for at least 6 months. The primary objective was to evaluate the proportion of patients achieving no evidence of disease activity (NEDA)-3 status, which is characterized by the absence of relapses, confirmed disability worsening, and new or enlarging MRI lesions, over time. Secondary objectives included assessing the proportion of patients meeting each NEDA-3 criterion, changes in motor and cognitive function, as well as the incidence of adverse events and treatment discontinuations. Results A total of 160 patients with MS were enrolled, including 125 patients treated with teriflunomide for at least 1 year (≥ 1-year completers) and 71 patients treated for at least 2 years (≥ 2-year completers). A total of 85.63% of the overall population achieved clinical NEDA-3 status at 6 months of teriflunomide treatment, and 71.20% of ≥ 1-year completers achieved NEDA-3 status at 12 months of teriflunomide treatment. The median timed 25-foot walk test (T25FW), nine-hole peg test (9-HPT), and paced auditory serial addition test (PASAT) results were relatively stable before and after treatment. Conclusion Medium- to long-term MS disease activity, as indicated by NEDA-3 status, is well controlled in patients treated with continuous teriflunomide treatment in real-world settings.
- 16 May 2024
- Published by Springer Nature in Neurology and Therapy
- Vol. 13 (4) , 1117-1133
Open AccessSustained Effectiveness and Safety Over Time of Teriflunomide in Chinese Patients with Relapsing Multiple Sclerosis in the Greater Bay Area of China: Insights from Real-World Data
Introduction The real-world data on the medium- to long-term effectiveness and safety of teriflunomide in Chinese patients with relapsing multiple sclerosis (MS) is limited. Therefore, this study aims to assess the treatment outcomes of teriflunomide in Chinese patients with MS over a medium- to long-term period. Methods This cohort study was carried out in three tertiary hospitals and regional MS centers located in the Greater Bay Area of China. We obtained the historical clinical data of patients who underwent teriflunomide treatment for at least 6 months. The primary objective was to evaluate the proportion of patients achieving no evidence of disease activity (NEDA)-3 status, which is characterized by the absence of relapses, confirmed disability worsening, and new or enlarging MRI lesions, over time. Secondary objectives included assessing the proportion of patients meeting each NEDA-3 criterion, changes in motor and cognitive function, as well as the incidence of adverse events and treatment discontinuations. Results A total of 160 patients with MS were enrolled, including 125 patients treated with teriflunomide for at least 1 year (≥ 1-year completers) and 71 patients treated for at least 2 years (≥ 2-year completers). A total of 85.63% of the overall population achieved clinical NEDA-3 status at 6 months of teriflunomide treatment, and 71.20% of ≥ 1-year completers achieved NEDA-3 status at 12 months of teriflunomide treatment. The median timed 25-foot walk test (T25FW), nine-hole peg test (9-HPT), and paced auditory serial addition test (PASAT) results were relatively stable before and after treatment. Conclusion Medium- to long-term MS disease activity, as indicated by NEDA-3 status, is well controlled in patients treated with continuous teriflunomide treatment in real-world settings.
- Open Access
- 1 January 2022
- Published by XMLink in Journal of Clinical Neurology
- Vol. 18 (4) , 453-462
Disease Course and Outcomes in Patients With the Limited Form of Neuromyelitis Optica Spectrum Disorders and Negative AQP4-IgG Serology at Disease Onset: A Prospective Cohort Study
Chen X, et al. J Clin Neurol. 2022 Jul;18(4):453-462. https://doi.org/10.3988/jcn.2022.18.4.453
- 1 January 2022
- Published by XMLink in Journal of Clinical Neurology
- Vol. 18 (4) , 453-462
Open AccessDisease Course and Outcomes in Patients With the Limited Form of Neuromyelitis Optica Spectrum Disorders and Negative AQP4-IgG Serology at Disease Onset: A Prospective Cohort Study
Chen X, et al. J Clin Neurol. 2022 Jul;18(4):453-462. https://doi.org/10.3988/jcn.2022.18.4.453